Plant-based GI Napo Pharmaceuticals focuses on plant-derived, non-opioid gastrointestinal prescription medicines, presenting opportunities to position products with safety-conscious clinicians and pediatric gastroenterology specialists who favor natural, sustainable therapies.

Pediatric Expansion Recent activity highlights presentations on pediatric intestinal failure and adjunctive therapies at ESPGHAN, indicating a clear market focus in pediatric GI and potential collaborations with hospitals, clinicians, and patient support programs for pediatric patients.

Europe Access Jaguar Health owns a majority stake in Napo Therapeutics S.p.A. to expand crofelemer access in Europe, suggesting sales opportunities through European distributors, regulatory approvals, and local partnerships to accelerate market presence.

Support Programs Evidence of patient access and reimbursement initiatives (iAssist and partnerships with AssistRx) signals ready-to-pitch value propositions around payer engagement, prior authorization, and patient assistance services to streamline adoption.

Strategic Partnerships Active collaborations within Jaguar’s ecosystem (Napo EU, Magdalena Biosciences, and Animal Health portfolio) present cross-sell opportunities for integrated GI solutions, companion animal applications, and joint development programs with strategic partners.